JPWO2019232306A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2019232306A5
JPWO2019232306A5 JP2020566936A JP2020566936A JPWO2019232306A5 JP WO2019232306 A5 JPWO2019232306 A5 JP WO2019232306A5 JP 2020566936 A JP2020566936 A JP 2020566936A JP 2020566936 A JP2020566936 A JP 2020566936A JP WO2019232306 A5 JPWO2019232306 A5 JP WO2019232306A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
composition according
cftr
patient
acevirstat
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020566936A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021525763A (ja
JP7386815B2 (ja
JP2021525763A5 (https=
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/034810 external-priority patent/WO2019232306A1/en
Publication of JP2021525763A publication Critical patent/JP2021525763A/ja
Publication of JPWO2019232306A5 publication Critical patent/JPWO2019232306A5/ja
Publication of JP2021525763A5 publication Critical patent/JP2021525763A5/ja
Priority to JP2023193448A priority Critical patent/JP7603775B2/ja
Application granted granted Critical
Publication of JP7386815B2 publication Critical patent/JP7386815B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020566936A 2018-05-31 2019-05-31 呼吸器疾患患者の肺増悪を軽減する方法 Active JP7386815B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023193448A JP7603775B2 (ja) 2018-05-31 2023-11-14 呼吸器疾患患者の肺増悪を軽減する方法

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862678964P 2018-05-31 2018-05-31
US62/678,964 2018-05-31
US201862702038P 2018-07-23 2018-07-23
US62/702,038 2018-07-23
PCT/US2019/034810 WO2019232306A1 (en) 2018-05-31 2019-05-31 Method of reducing pulmonary exacerbations in respiratory disease patients

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023193448A Division JP7603775B2 (ja) 2018-05-31 2023-11-14 呼吸器疾患患者の肺増悪を軽減する方法

Publications (4)

Publication Number Publication Date
JP2021525763A JP2021525763A (ja) 2021-09-27
JPWO2019232306A5 true JPWO2019232306A5 (https=) 2022-05-23
JP2021525763A5 JP2021525763A5 (https=) 2022-05-23
JP7386815B2 JP7386815B2 (ja) 2023-11-27

Family

ID=68694908

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020566936A Active JP7386815B2 (ja) 2018-05-31 2019-05-31 呼吸器疾患患者の肺増悪を軽減する方法
JP2023193448A Active JP7603775B2 (ja) 2018-05-31 2023-11-14 呼吸器疾患患者の肺増悪を軽減する方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023193448A Active JP7603775B2 (ja) 2018-05-31 2023-11-14 呼吸器疾患患者の肺増悪を軽減する方法

Country Status (6)

Country Link
US (3) US10898484B2 (https=)
EP (1) EP3801559B1 (https=)
JP (2) JP7386815B2 (https=)
AU (1) AU2019278935B2 (https=)
ES (1) ES3014615T3 (https=)
WO (1) WO2019232306A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3801559B1 (en) * 2018-05-31 2025-01-01 Celltaxis, LLC Method of reducing pulmonary exacerbations in respiratory disease patients
US20240016941A1 (en) * 2020-03-24 2024-01-18 Antabio Sas Combination therapy
CA3207882A1 (en) * 2021-01-15 2022-07-21 Children's Hospital Medical Center Methods for optimizing cftr-modulator therapy
WO2024254377A2 (en) * 2023-06-09 2024-12-12 Celltaxis, Llc Methods of treating lipedema and lymphatic disease of the subcutaneous tissue

Family Cites Families (91)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL6815872A (https=) 1967-11-22 1969-05-27
JPS5614663B2 (https=) 1971-08-21 1981-04-06
US4582833A (en) 1984-04-16 1986-04-15 American Cyanamid Company 2-(substituted-1-piperazinyl)[1,2,4]triazolo[1,5-a]pyrimidines
US4576943A (en) 1984-10-09 1986-03-18 American Cyanamid Company Pyrazolo[1,5-a]pyrimidines
US5308852A (en) 1992-06-29 1994-05-03 Merck Frosst Canada, Inc. Heteroarylnaphthalenes as inhibitors of leukotriene biosynthesis
US6506876B1 (en) 1994-10-11 2003-01-14 G.D. Searle & Co. LTA4 hydrolase inhibitor pharmaceutical compositions and methods of use
AU1952597A (en) 1996-02-13 1997-09-02 G.D. Searle & Co. Combinations, having immunosuppressive effects, containing cyclooxygenase-2 inhibitor and a leukotriene a4 hydrolase inhibitor
US5952349A (en) 1996-07-10 1999-09-14 Schering Corporation Muscarinic antagonists for treating memory loss
JP2000516611A (ja) 1996-08-14 2000-12-12 ワーナー―ランバート・コンパニー Mcp―1アンタゴニストとしての2―フェニルベンズイミダゾール誘導体
US6309561B1 (en) 1997-12-24 2001-10-30 3M Innovative Properties Company Liquid crystal compounds having a chiral fluorinated terminal portion
US6380203B1 (en) 1998-01-14 2002-04-30 Merck & Co., Inc. Angiogenesis inhibitors
GB9815880D0 (en) 1998-07-21 1998-09-16 Pfizer Ltd Heterocycles
GB9919776D0 (en) 1998-08-31 1999-10-27 Zeneca Ltd Compoujnds
AR023659A1 (es) 1998-09-18 2002-09-04 Vertex Pharma Un compuesto inhibidor de p38, una composicion farmaceutica que lo comprende y el uso de dicha composicion en el tratamiento y prevencion de estados patologicos
US6699873B1 (en) 1999-08-04 2004-03-02 Millennium Pharmaceuticals, Inc. Melanocortin-4 receptor binding compounds and methods of use thereof
US6924313B1 (en) 1999-09-23 2005-08-02 Pfizer Inc. Substituted tertiary-heteroalkylamines useful for inhibiting cholesteryl ester transfer protein activity
WO2001056990A2 (en) 2000-02-03 2001-08-09 Eli Lilly And Company Pyridine derivates as potentiators of glutamate receptors
US6552023B2 (en) 2000-02-22 2003-04-22 Cv Therapeutics, Inc. Aralkyl substituted piperazine compounds
US6451798B2 (en) 2000-02-22 2002-09-17 Cv Therapeutics, Inc. Substituted alkyl piperazine derivatives
JP2001354657A (ja) 2000-06-09 2001-12-25 Sds Biotech:Kk 置換ピペラジン誘導体及び農園芸用殺菌剤
EP1170353B1 (en) 2000-07-06 2005-11-02 Fuji Photo Film Co., Ltd. Liquid crystal composition comprising liquid crystal molecules and aligment promoter
WO2002064211A1 (en) 2001-02-09 2002-08-22 Merck & Co., Inc. Thrombin inhibitors
EP1372655B1 (en) 2001-03-02 2008-10-01 Merck Frosst Canada Ltd. Cathepsin cysteine protease inhibitors
AUPR362001A0 (en) 2001-03-08 2001-04-05 Fujisawa Pharmaceutical Co., Ltd. New compound
FR2826011B1 (fr) 2001-06-14 2004-12-10 Oreal Nouveaux derives de la 7-oxo-dhea et utilisation cosmetique
SE0102616D0 (sv) 2001-07-25 2001-07-25 Astrazeneca Ab Novel compounds
EP1435946B8 (en) 2001-09-14 2013-12-18 Amgen Inc. Linked biaryl compounds
AU2002363236A1 (en) 2001-10-30 2003-05-12 Millennium Pharmaceuticals, Inc. Compounds, pharmaceutical compositions and methods of use therefor
EP1693061A1 (en) 2002-10-04 2006-08-23 Ucb, S.A. Use of 4-aminoderivatives for the preparation of a medicament for treating neurological diseases
US7851486B2 (en) 2002-10-17 2010-12-14 Decode Genetics Ehf. Susceptibility gene for myocardial infarction, stroke, and PAOD; methods of treatment
AU2003290527A1 (en) 2002-10-17 2004-05-04 Decode Genetics Ehf. Susceptibility gene for myocardial infarction
WO2004058683A2 (en) 2002-12-20 2004-07-15 Migenix Corp. Ligands of adenine nucleotide translocase (ant) and compositions and methods related thereto
WO2004089410A1 (ja) 2003-04-03 2004-10-21 Kyowa Hakko Kogyo Co., Ltd. 神経因性疼痛の予防及び/または治療剤
WO2004099164A1 (en) 2003-05-02 2004-11-18 Rigel Pharmaceuticals, Inc. Substituted diphenyl isoxazoles, pyrazoles and oxadiazoles useful for treating hcv infection
JP2005008581A (ja) 2003-06-20 2005-01-13 Kissei Pharmaceut Co Ltd 新規なピラゾロ[1,5−a]ピリミジン誘導体、それを含有する医薬組成物およびそれらの用途
CN1856490A (zh) 2003-07-28 2006-11-01 詹森药业有限公司 苯并咪唑、苯并噻唑和苯并噁唑衍生物及其作为lta4h调节剂的应用
US20050272051A1 (en) 2003-09-17 2005-12-08 Decode Genetics Ehf. Methods of preventing or treating recurrence of myocardial infarction
WO2005033079A1 (ja) 2003-09-30 2005-04-14 Eisai Co., Ltd. ヘテロ環化合物を含有する新規な抗真菌剤
GB0326632D0 (en) 2003-11-14 2003-12-17 Jagotec Ag Dry powder formulations
DE10356579A1 (de) 2003-12-04 2005-07-07 Merck Patent Gmbh Aminderivate
SE0303480D0 (sv) 2003-12-19 2003-12-19 Biovitrum Ab Benzofuranes
WO2005066238A1 (en) 2003-12-30 2005-07-21 3M Innovative Properties Company Medicinal compositions and method for the preparation thereof
DE602005015682D1 (de) 2004-02-04 2009-09-10 Neurosearch As Dimere azacyclische verbindungen und deren verwendung
WO2006033795A2 (en) 2004-09-17 2006-03-30 Wyeth Substituted pyrazolo [1, 5-a] pyrimidines for inhibiting abnormal cell growth
ES2570332T3 (es) 2005-03-16 2016-05-17 Meda Pharma Gmbh & Co Kg La combinación de anticolinérgicos y antagonistas del receptor de leucotrieno para el tratamiento de enfermedades respiratorias
US20060223792A1 (en) 2005-03-31 2006-10-05 Butler Christopher R Phenyl and pyridyl LTA4H modulators
GB0514018D0 (en) 2005-07-07 2005-08-17 Ionix Pharmaceuticals Ltd Chemical compounds
US20070078263A1 (en) 2005-09-21 2007-04-05 Decode Chemistry, Inc. Biaryl substituted heterocycle inhibitors of lta4h for treating inflammation
CN1947717B (zh) 2005-10-14 2012-09-26 卓敏 选择性抑制腺苷酸环化酶1的化合物在制备用于治疗神经性疼痛和炎性疼痛的药物中的应用
DE102005049954A1 (de) 2005-10-19 2007-05-31 Sanofi-Aventis Deutschland Gmbh Triazolopyridin-derivate als Inhibitoren von Lipasen und Phospholipasen
WO2007079078A1 (en) 2005-12-29 2007-07-12 Bayer Schering Pharma Aktiengesellschaft Diamine derivatives as inhibitors of leukotriene a4 hydrolase
WO2007079003A2 (en) 2005-12-29 2007-07-12 Bayer Schering Pharma Aktiengesellschaft Amide inhibitors of leukotriene a4 hydrolase
CN102633783A (zh) 2006-02-10 2012-08-15 转化技术制药公司 作为Aurora激酶抑制剂的苯并唑系衍生物、组合物和使用方法
US20100029619A1 (en) 2006-08-04 2010-02-04 Takeda Pharmaceutical Company Limted Fused heterocyclic compound
JP5167265B2 (ja) 2006-10-19 2013-03-21 エフ.ホフマン−ラ ロシュ アーゲー 微量アミン関連受容体に親和性を有するアミノメチル−2−イミダゾール
HRP20170621T1 (hr) 2006-12-14 2017-07-28 Janssen Pharmaceutica N.V. Postupak za pripremanje derivata piperazinil i diazepanil benzamida
FR2911140B1 (fr) 2007-01-05 2009-02-20 Sanofi Aventis Sa Nouveaux derives de 2-anilino 4-heteroaryle pyrimides, leur preparation a titre de medicaments, compositions pharmaceutiques et notamment comme inhibiteurs de ikk
FR2911138B1 (fr) 2007-01-05 2009-02-20 Sanofi Aventis Sa Nouveaux derives de n, n'-2,4-dianilinopyrimidines, leur preparation a titre de medicaments, compositions pharmaceutiques et notamment comme inhibiteurs de ikk
FR2911139A1 (fr) 2007-01-05 2008-07-11 Sanofi Aventis Sa Nouveaux derives de phenyl-(4-phenyl-pyrimidin-2-yl)amines, leur preparation a titre de medicaments, compositions pharmaceutiques et notamment comme inhibiteurs de ikk
CN101687844B (zh) 2007-07-02 2013-11-13 弗·哈夫曼-拉罗切有限公司 用作ccr2受体拮抗剂的咪唑衍生物
AR068498A1 (es) 2007-09-27 2009-11-18 Merck & Co Inc Compuestos de oxadiazol para inhibicion de biosintesis de leucotrienos
WO2009074829A1 (en) 2007-12-12 2009-06-18 Astrazeneca Ab Peptidyl nitriles and use thereof as dipeptidyl peptidase i inhibitors
US20110009429A1 (en) 2008-02-26 2011-01-13 Paul Oakley Heterocyclic compounds as inhibitors of cxcr2
FR2928070A1 (fr) 2008-02-27 2009-09-04 Sumitomo Chemical Co Composition agricole, utilisation d'un compose pour sa production et procede pour matriser ou prevenir les maladies des plantes.
US20100029657A1 (en) 2008-02-29 2010-02-04 Wyeth Bridged, Bicyclic Heterocyclic or Spiro Bicyclic Heterocyclic Derivatives of Pyrazolo[1, 5-A]Pyrimidines, Methods for Preparation and Uses Thereof
SI2336125T1 (sl) 2008-04-11 2013-04-30 Janssen Pharmaceutica N.V. Tiazolopiridin-2-iloksi-fenil in tiazolopirazin-2-iloksi-fenil amini kot modulatorji levkotrien a4 hidrolaze
EP2110374A1 (en) 2008-04-18 2009-10-21 Merck Sante Benzofurane, benzothiophene, benzothiazol derivatives as FXR modulators
WO2010011912A1 (en) 2008-07-25 2010-01-28 Smithkline Beecham Corporation Trpv4 antagonists
ES2399179T3 (es) 2008-08-07 2013-03-26 Pulmagen Therapeutics (Inflammation) Limited Tratamiento de enfermedad respiratoria
RU2589823C2 (ru) 2009-04-09 2016-07-10 Алкермес Фарма Айэленд Лимитед Композиция для доставки лекарственных средств
CN102030700B (zh) 2009-09-30 2016-06-01 中国医学科学院药物研究所 苯甲酰胺基羧酸类化合物及其制法和药物用途
JP5781527B2 (ja) 2009-10-30 2015-09-24 ヤンセン ファーマシューティカ エヌ.ベー. 4−置換−2−フェノキシ−フェニルアミンデルオピオイド受容体調節因子
PH12012501068A1 (en) 2009-12-07 2013-02-04 Targacept Inc 3,6-diazabicyclo [3.1.1] heptanes as neuronal nicotinic acetylcholine receptor ligands
BR112013002112B1 (pt) 2010-07-29 2021-04-06 Rigel Pharmaceuticals, Inc. Composto, composição farmacêutica, e, uso de um composto, ou de um respectivo sal farmaceuticamente aceitável, ou de uma composição
WO2012067822A1 (en) 2010-11-16 2012-05-24 Abbott Laboratories Pyrazolo [1, 5 -a] pyrimidin potassium channel modulators
CA2835617C (en) 2011-03-14 2020-07-21 Boehringer Ingelheim International Gmbh Benzodioxane inhibitors of leukotriene production
PH12013501882A1 (en) 2011-03-15 2013-10-14 Rib X Pharmaceuticals Inc Antimicrobial agents
KR101862291B1 (ko) 2011-04-12 2018-05-29 모레 매트릭스 인코포레이티드 이상 섬유모세포 증식 및 세포외 기질 침착을 특징으로 하는 질병, 질환, 또는 과정을 예방하거나 치료하기 위한 조성물 및 방법
WO2012162407A1 (en) 2011-05-23 2012-11-29 Janssen Pharmaceutica Nv Picolinamido - propanoic acid derivatives useful as glucagon receptor antagonists
EP2589381B1 (en) 2011-11-04 2016-08-31 Rabindra Tirouvanziam Compositions for improving or preserving lung function in a patient with a pulmonary disorder
CN103159742B (zh) 2011-12-16 2015-08-12 北京韩美药品有限公司 5-氯嘧啶类化合物及其作为egfr酪氨酸激酶抑制剂的应用
US9006235B2 (en) 2012-03-06 2015-04-14 Bristol-Myers Squibb Company Inhibitors of human immunodeficiency virus replication
US9233089B2 (en) 2012-03-23 2016-01-12 The Board Of Trustees Of The Leland Stanford Junior University Treatment of pulmonary hypertension with leukotriene inhibitors
ES2864862T3 (es) * 2013-03-12 2021-10-14 Celltaxis Llc Métodos de inhibición de la leucotrieno A4 hidrolasa
MX2015011677A (es) 2013-03-14 2016-07-08 Celtaxsys Inc Inhibidores de leucotrieno a4 hidrolasa.
RU2678196C2 (ru) 2013-03-14 2019-01-24 Селтакссис, Инк. Производные 2-фениламино-3-цианопиразоло[1,5-а]пиримидина, полезные в качестве ингибитора лейкотриен-a4-гидролазы
WO2014152536A2 (en) 2013-03-14 2014-09-25 Celtaxsys, Inc. Inhibitors of leukotriene a4 hydrolase
US9480676B2 (en) * 2014-05-15 2016-11-01 Celgene Corporation Use of PDE4 inhibitors and combinations thereof for the treatment of cystic fibrosis
MA41253A (fr) * 2014-12-23 2017-10-31 Proteostasis Therapeutics Inc Composés, compositions et procédés pour augmenter l'activité du cftr
HUP1600271A2 (hu) * 2016-04-25 2017-10-30 Druggability Tech Ip Holdco Ltd Ivacaftor és Lumacaftor sóinak és származékainak komplexei, eljárás azok elõállítására és azok gyógyszerészetileg elfogadható készítményei
EP3801559B1 (en) * 2018-05-31 2025-01-01 Celltaxis, LLC Method of reducing pulmonary exacerbations in respiratory disease patients

Similar Documents

Publication Publication Date Title
JP6244497B1 (ja) 選択的s1p1レセプターアゴニストの投与法
DE60132723T2 (de) Zusammensetzungen bestehend aus Dipeptidylpeptidase-IV Inhibitoren und Antidiabetica
KR102319078B1 (ko) 궤양성 대장염의 치료용 의약 조성물
Keating Nintedanib: a review of its use in patients with idiopathic pulmonary fibrosis
EP2969010B1 (en) Use of levocetirizine and montelukast in the treatment of autoimmune disorders
JP2021525763A5 (https=)
JP6313414B2 (ja) 外傷性傷害の処置におけるレボセチリジン及びモンテルカストの使用
JP2018123159A (ja) 神経変性およびその他の疾患の治療用組成物および方法
Scosyrev et al. Cardiovascular safety of mometasone/indacaterol and mometasone/indacaterol/glycopyrronium once-daily fixed-dose combinations in asthma: pooled analysis of phase 3 trials
AU2025271046A1 (en) New therapeutic combinations for the treatment of progressive fibrosing interstitial lung diseases
Liu et al. Ivarmacitinib, a selective Janus kinase 1 inhibitor, in patients with moderate-to-severe active rheumatoid arthritis and inadequate response to conventional synthetic DMARDs: results from a phase III randomised clinical trial
JP2021525763A (ja) 呼吸器疾患患者の肺増悪を軽減する方法
CN116685353A (zh) 血管性水肿的预防和治疗
EP4426307B1 (en) New oral pharmaceutical composition and dose regimen for the therapy of progressive fibrosing interstitial lung diseases
JPWO2019232306A5 (https=)
TW201210586A (en) Methods of using diacerein as an adjunctive therapy for diabetes
US20240024434A1 (en) Mitapivat therapy and modulators of cytochrome p450
JP2022518527A (ja) パーキンソン病の患者を治療する方法
JP2022506019A (ja) 高用量の放出調節フペルジン製剤の使用
TW202408522A (zh) 一種稠環嘧啶類化合物的用途
JP2012031141A (ja) 骨髄異形性症候群を治療するための組成物および方法
WO2023193705A1 (zh) 西奥罗尼在抗胰腺癌中的用途
CA3234440A1 (en) 1h-1,2,3-triazole-4-carboxylic acids for treatment of hyperoxaluria and kidney stones
Bel Haj Ali et al. Reply to Mori et al
HK40115216A (en) New oral pharmaceutical composition and dose regimen for the therapy of progressive fibrosing interstitial lung diseases